Palisade Bio Inc (PALI) - Total Liabilities
Based on the latest financial reports, Palisade Bio Inc (PALI) has total liabilities worth $5.95 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Palisade Bio Inc (PALI) equity growth momentum to track the company's year-over-year net asset growth rate.
Palisade Bio Inc - Total Liabilities Trend (2005–2025)
This chart illustrates how Palisade Bio Inc's total liabilities have evolved over time, based on quarterly financial data.
Palisade Bio Inc Competitors by Total Liabilities
The table below lists competitors of Palisade Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangzhou Seagull Kitchen And Bath Products Co Ltd
SHE:002084
|
China | CN¥1.44 Billion |
|
Antibiotice Ia
RO:ATB
|
Romania | RON548.43 Million |
|
Zoneco Group Co Ltd
SHE:002069
|
China | CN¥2.10 Billion |
|
Beijing SunwayWorld Science & Technology Co. Ltd.
SHE:301159
|
China | CN¥149.42 Million |
|
Selvaag Bolig ASA
OL:SBO
|
Norway | Nkr4.40 Billion |
|
Svedbergs i Dalstorp AB (publ)
ST:SVED-B
|
Sweden | Skr1.59 Billion |
|
Vetropack Holding SA
SW:VETN
|
Switzerland | CHF479.00 Million |
|
GENERALFINANCE SPA
F:VG30
|
Germany | €743.76 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Palisade Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PALI market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 23.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Palisade Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Palisade Bio Inc (2005–2025)
The table below shows the annual total liabilities of Palisade Bio Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.96 Million | +46.52% |
| 2024-12-31 | $3.39 Million | +23.69% |
| 2023-12-31 | $2.74 Million | -16.60% |
| 2022-12-31 | $3.28 Million | -36.20% |
| 2021-12-31 | $5.15 Million | -49.13% |
| 2020-12-31 | $10.12 Million | +594.01% |
| 2019-12-31 | $1.46 Million | -10.83% |
| 2018-12-31 | $1.63 Million | -69.55% |
| 2017-12-31 | $5.37 Million | -52.37% |
| 2016-12-31 | $11.27 Million | +12.94% |
| 2015-12-31 | $9.98 Million | -17.67% |
| 2014-12-31 | $12.12 Million | +10.27% |
| 2013-12-31 | $11.00 Million | +518.60% |
| 2012-12-31 | $1.78 Million | -26.74% |
| 2011-12-31 | $2.43 Million | -11.35% |
| 2010-12-31 | $2.74 Million | -65.88% |
| 2009-12-31 | $8.02 Million | +533.97% |
| 2008-12-31 | $1.27 Million | +24.47% |
| 2007-12-31 | $1.02 Million | +167.30% |
| 2006-12-31 | $380.36K | -63.07% |
| 2005-12-31 | $1.03 Million | -- |
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibroste… Read more